ClinicalTrials.gg
RecruitingNCT07622368Updated Jul 14, 2026

A Study of IBI3031 in Participants With Thyroid Eye Disease

A Phase 1 interventional study of IBI3031 and placebo in Thyroid Eye Disease, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Planned enrollment
22nd of 45
66 · median 64
Started
2026
with 10 others
Phase 1
6 of 55
3 open now
Primary completion
2027-06
later than 14 of 27 live
Registered
51st of 55
by date
Lead sponsor
6 of 55
Innovent Biologics (Suzhou) Co. Ltd.

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 22nd largest by planned enrollment of the 45 interventional ones that give a count, is one of 11 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 14 of the 27 other live ones, and was the 51st registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of IBI3031 administered via subcutaneous or intravenous injection.

Read the detailed description

IBI3031 is an IGF-1R(Insulin-like growth factor 1 receptor)/TSHR(Thyroid-stimulating hormone receptor) bispecific antibody with potential synergistic therapeutic efficacy in TED and modulatory effects on thyroid function. As the first-in-human trial of IBI3031, this study evaluates the safety, tolerability, PK(Pharmacokinetics)/PD(Pharmacodynamics) profiles, immunogenicity, and efficacy of IBI3031 in TED participants. The trial is conducted in two stages: Stage 1- a single-ascending-dose (SAD) study involving single SC or IV administration of IBI3031; Stage 2- a multiple-ascending-dose (MAD) study involving three SC administrations of IBI3031. Approximately 66 TED participants are planned for enrollment: 36 in Stage 1 (allocated at a 3:1 ratio) and 30 in Stage 2 (allocated at a 4:1 ratio).

03

Conditions studied

  • Thyroid Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Written .
  2. Aged between 18 and 75 years at screening.
  3. Weight between 45 kg and 100 kg.
  4. Moderate-to-severe active TED:

    • CAS ≥ 3 in the study eye at screening and baseline;
    • Usually associated with at least two of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal, and/or inconstant or constant diplopia;
    • ≤ 12 months since the onset of active TED symptoms according to subjects' chief complaint or medical record at screening;
  5. Exophthalmos ≥ 18 mm in the study eye at baseline. (Only applicable to Stage 2)
  6. Participants must be clinically and biochemically euthyroid, or have mild hypothyroidism or mild-to-moderate hyperthyroidism at screening.
  7. Positive for Thyrotrophin Receptor Antibody (TRAb) at screening.
  8. No prior treatment with antithyroid medications and/or thyroid hormone replacement therapy, or having taken antithyroid medications and/or thyroid hormone replacement therapy on a stable dose for at least 6 weeks prior to the first dose, or having not been treated with antithyroid medications and/or thyroid hormone replacement therapy due to intolerable side effects for at least 6 weeks prior to the first dose.
  9. Infertile female participants or fertile female participants with negative blood pregnancy test results during the screening period and agree to take measures from screening to 120 days after the last dose; male participants should agree to use contraceptive measures from screening to 120 days after the last dose.

Key Exclusion Criteria:

Participants to be excluded (Participants meeting any of the following criteria will be regarded as ineligible):

  1. The CAS of the study eye at baseline is reduced by ≥ 2 points compared with that at screening, or the proptosis of the study eye at baseline is reduced by ≥ 2 mm compared with that at screening;
  2. Participants previously diagnosed with dysthyroid optic neuropathy (DON), or with DON as determined by the investigator at screening;
  3. Patients with corneal ulcers that are not relieved after treatment at the investigator's discretion;
  4. Presence of other non-TED ophthalmic diseases that may affect the interpretation of study results or the safety of participants as determined by the investigator (e.g., proptosis not primarily caused by TED);
  5. At screening, clinical or laboratory evidence of significant hypothyroidism (presence of clinical symptoms of hypothyroidism, or FT3 or FT4 (Free Thyroxine)\<0.5×lower limit of normal [LLN], or TSH>1.5× [ULN]); or severe hyperthyroidism during the screening period (FT3 and FT4(Free Thyroxine)>2×ULN, or presence of thyroid storm).
  6. Other medical history and abnormal test results during the screening period that are judged by the investigator to be , may cause the participant to fail to comply with the study protocol or complete the trial, or endanger safety, including but not limited to:

    • History of hepatic insufficiency ( Class B or C) or liver cirrhosis; (AST) or alanine aminotransferase (ALT) > 2 × ULN at screening;
    • (GFR) \< 60 ml/min/1.73 m2;
    • Poorly controlled diabetes mellitus or hypertension;
    • Confirmed or clinically suspected inflammatory bowel disease, gastrointestinal bleeding, or peptic ulcer disease.
    • History of of chronic or recurrent infections; opportunistic infection within 180 days prior to screening;
    • Positive for antibody (HIV Ab), virus antibody (HCV Ab), non-specific syphilis antibody (e.g., RPR(Rapid Plasma Reagin), TRUST), virus surface antigen (HBsAg) or e-antigen (HBeAg), or interferon-gamma release assay (IGRA).
    • History of tinnitus or other hearing impairment in either ear during the screening period; or abnormal pure tone audiometry results (defined as an average bone conduction hearing threshold of ≥ 25 dB(decibe) at 0.5, 1, 2, and 4 kHz(kilohertz), or a bone conduction hearing threshold of ≥ 40 dB at any frequency);
  7. Scheduled radioactive iodine therapy or thyroidectomy at any time before screening or during the study;
  8. Scheduled orbital radiotherapy at any time before screening or during the study, or surgical treatment for TED, including orbital decompression, strabismus surgery, and eyelid surgery;
  9. Cumulative dose of used to treat TED ≥ 1 g of methylprednisolone equivalents within 90 days prior to screening;
  10. Oral or intravenous glucocorticoids within 30 days prior to screening;
  11. Peribulbar/periorbital injection of glucocorticoids within 90 days prior to screening;
  12. Oral or intravenous administration of any other non-steroidal within 90 days prior to screening;
  13. Use of glucocorticoid eye drops/ointments or use of non-steroidal immunosuppressant eye drops within 14 days prior to screening;
  14. Received antibody therapy targeting IGF-1R, TSHR, CD20(cluster of differentiation antigen 20), IL-6, or IL-6 receptor (IL-6R) at any time before screening;
  15. Received any other TED therapeutic drugs under development (including but not limited to biologics targeting IGF-1R, FcRn(neonatal Fc recepto), IL-6, or IL-6R) at any time before screening;
  16. Use of any other monoclonal antibody within 90 days prior to screening;
  17. Have received within 180 days prior to screening, or plan to receive live vaccines during the study;
  18. Female participants in pregnancy or lactation.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Placebo comparator
    SAD Dose 4 - Placebo Control Group

    Subjects receive matching placebo to the treatment group.

    Drug: placebo

  • Experimental
    MAD Dose 2- IBI3031A101 Treatment Group

    Multiple ascending dose (MAD) phase. Subjects receive repeated doses of IBI3031A101 to evaluate safety, tolerability and steady-state pharmacokinetics.

    Drug: IBI3031

  • Experimental
    SAD Dose 4 - IBI3031A101 Treatment Group

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.

    Drug: IBI3031

  • Placebo comparator
    MAD Dose 1 - Placebo Control Group

    Multiple ascending dose (MAD) phase. Subjects receive matching placebo to the treatment group.

    Drug: placebo

  • Experimental
    MAD Dose 1- IBI3031A101 Treatment Group

    Multiple ascending dose (MAD) phase. Subjects receive repeated doses of IBI3031A101 to evaluate safety, tolerability and steady-state pharmacokinetics.

    Drug: IBI3031

  • Placebo comparator
    MAD Dose 3 - Placebo Control Group

    Multiple ascending dose (MAD) phase. Subjects receive matching placebo to the treatment group.

    Drug: placebo

  • Experimental
    SAD Dose 5 - IBI3031A101 Treatment Group

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.

    Drug: IBI3031

  • Placebo comparator
    MAD Dose 2 - Placebo Control Group

    Multiple ascending dose (MAD) phase. Subjects receive matching placebo to the treatment group.

    Drug: placebo

  • Placebo comparator
    SAD - Dose 1 - Placebo Control Group

    Subjects receive matching placebo to the treatment group.

    Drug: placebo

  • Experimental
    SAD Dose 3 - IBI3031A101 Treatment Group

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.(at the same dose level as Arm 2 but via \[different route/method)

    Drug: IBI3031

  • Experimental
    SAD Dose 2 - IBI3031A101 Treatment Group

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.

    Drug: IBI3031

  • Placebo comparator
    SAD Dose 5 - Placebo Control Group

    Subjects receive matching placebo to the treatment group.

    Drug: placebo

  • Placebo comparator
    SAD Dose 3 - Placebo Control Group

    Subjects receive matching placebo to the treatment group.

    Drug: placebo

  • Experimental
    MAD Dose 3- IBI3031A101 Treatment Group

    Multiple ascending dose (MAD) phase. Subjects receive repeated doses of IBI3031A101 to evaluate safety, tolerability and steady-state pharmacokinetics.

    Drug: IBI3031

  • Placebo comparator
    SAD - Dose 2 - Placebo Control Group

    Subjects receive matching placebo to the treatment group.

    Drug: placebo

  • Experimental
    SAD Dose 1 - IBI3031A101 Treatment Group

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.

    Drug: IBI3031

Interventions

  • DrugIBI3031

    subcutaneous injection or intravenous infusion.

  • Drugplacebo

    subcutaneous injection or intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Number, incidence rate, severity, and association with the study drug of Adverse Events (AEs)

    The number, incidence rate, severity, and association with the study drug of all AEs occurring throughout the trial will be summarized.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  2. Number, incidence rate, severity, and association with the study drug of Treatment-Emergent Adverse Events (TEAEs)

    The number, incidence rate, severity, and association with the study drug of all TEAEs after study drug administration will be summarized.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  3. Number, incidence rate, severity, and association with the study drug of Serious Adverse Events (SAEs)

    The number, incidence rate, severity, and association with the study drug of all SAEs will be summarized.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  4. Change in systolic and diastolic blood pressure after dosing in each dose group(Unit of Measure: mmHg)

    Systolic and diastolic blood pressure will be measured and recorded at each specified time point

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  5. Number of participants with clinically significant abnormal findings in complete physical examination(Unit of Measure: participants)

    A complete physical examination will be performed at each specified time point, including assessment of general appearance, respiratory system, cardiovascular system, abdomen, skin, head and neck (including ears, nose, and throat), lymph nodes, thyroid gland, musculoskeletal system (including spine and extremities), and neurological system. Any finding that is new or worsened from baseline and deemed clinically significant by the investigator will be

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  6. Changes in hematology laboratory parameters before and after dosing in each dose group

    Changes in hematology parameters including white blood cell count, red blood cell count, hemoglobin, and platelet count will be recorded.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  7. Changes in blood chemistry laboratory parameters before and after dosing in each dose group

    Changes in blood chemistry parameters including liver and renal function, electrolytes, and blood glucose will be recorded.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  8. Changes in urinalysis laboratory parameters before and after dosing in each dose group

    Changes in urinalysis parameters including urine protein, urine occult blood, and urine leukocytes will be recorded.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  9. Changes in thyroid function laboratory parameters before and after dosing in each dose group

    Changes in thyroid function parameters including thyroid-stimulating hormone, free triiodothyronine, and free thyroxine will be recorded.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  10. Number of subjects with abnormal ECG changes before and after administration in each dose group

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  11. Changes in pure-tone audiometry results before and after dosing in each dose group

    Changes in hearing thresholds at each frequency (500 Hz, 1000 Hz, 2000 Hz, 4000 Hz) will be recorded.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  12. Change in heart rate after dosing in each dose group (Unit of Measure: beats per minute)

    Heart rate will be measured and recorded at each specified time point.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  13. Change in body temperature after dosing in each dose group(Unit of Measure: °C)

    Body temperature will be measured and recorded at each specified time point.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  14. Change in respiratory rate after dosing in each dose group( Unit of Measure: breaths per minute)

    Respiratory rate will be measured and recorded at each specified time point.

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

Secondary outcomes

  1. Area Under the Curve (AUC) of the serum concentration-time profile

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  2. Maximum Concentration (Cmax) of the drug in serum

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  3. Clearance (CL)

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  4. Volume of Distribution (Vd)

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  5. Elimination Half-life (t1/2)

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  6. Production of anti-drug antibodies (ADAs) and/or neutralizing antibodies (NAbs) in serum

    Time frame: up to Day 85 for SAD;up to Day 337 for MAD

  7. Proportion of participants with proptosis response

    Defined as a ≥2 mm reduction in proptosis in the study eye from baseline, without a ≥2 mm increase in proptosis in the fellow eye

    Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage

  8. Proportion of participants with overall response

    Defined as a ≥2-point reduction in the Clinical Activity Score (CAS) from baseline in the study eye, a ≥2 mm reduction in proptosis in the study eye from baseline, and no worsening in the fellow eye (worsening defined as a ≥2-point increase in CAS or a ≥2 mm increase in proptosis)

    Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage

  9. Number of subjects with changes in proptosis from baseline after dosing

    Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage

  10. Proportion of participants with CAS = 0 or 1

    Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage

  11. CAS change from baseline

    Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage

  12. Proportion of participants with diplopia response

    Defined as a ≥1-point reduction in diplopia

    Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage

  13. Total score of the Graves' Ophthalmopathy Quality of Life

    The effect of thyroid eye disease on social activities and appearance during the past 1 week.

    Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
Jun 3, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Jun 15, 2027
CompletionEst.
Dec 28, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07622368
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jun 30, 2026
Primary completion
Jun 15, 2027 (estimated)
Completion
Dec 28, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Zhongyan shan
Contact
Shanzhongyan@medmal.com.cn
024-83282152
funan liu
Contact
lfn540@126.com
024-83281137

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion